TY - JOUR
T1 - Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care
T2 - I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
AU - I-MOVE-COVID-19 primary care study team
AU - I-MOVE-COVID-19 primary care study team (in addition to authors above)
AU - Kissling, Esther
AU - Hooiveld, Mariette
AU - Sandonis Martín, Virginia
AU - Martínez-Baz, Iván
AU - William, Naoma
AU - Vilcu, Ana Maria
AU - Mazagatos, Clara
AU - Domegan, Lisa
AU - de Lusignan, Simon
AU - Meijer, Adam
AU - Machado, Ausenda
AU - Brytting, Mia
AU - Casado, Itziar
AU - Murray, Josephine L.K.
AU - Belhillil, Sylvie
AU - Larrauri, Amparo
AU - O'Donnell, Joan
AU - Tsang, Ruby
AU - de Lange, Marit
AU - Rodrigues, Ana Paula
AU - Riess, Maximilian
AU - Castilla, Jesús
AU - Hamilton, Mark
AU - Falchi, Alessandra
AU - Pozo, Francisco
AU - Dunford, Linda
AU - Cogdale, Jade
AU - Jansen, Tessa
AU - Guiomar, Raquel
AU - Enkirch, Theresa
AU - Burgui, Cristina
AU - Sigerson, Debbie
AU - Blanchon, Thierry
AU - Martínez Ochoa, Eva María
AU - Connell, Jeff
AU - Ellis, Joanna
AU - van Gageldonk-Lafeber, Rianne
AU - Kislaya, Irina
AU - Rose, Angela Mc
AU - Valenciano, Marta
PY - 2021/7/22
Y1 - 2021/7/22
N2 - We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.
AB - We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.
KW - COVID-19
KW - Europe
KW - SARS-CoV-2
KW - multicentre study
KW - test-negative design
KW - vaccine effectiveness
UR - http://www.scopus.com/inward/record.url?scp=85112153857&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2021.26.29.2100670
DO - 10.2807/1560-7917.ES.2021.26.29.2100670
M3 - Article
C2 - 34296676
AN - SCOPUS:85112153857
VL - 26
JO - Eurosurveillance
JF - Eurosurveillance
SN - 1025-496X
IS - 29
M1 - 2100670
ER -
